-Bloomberg
Zivo Bioscience Said USDA Letter Affirmed Agency Has Claimed Jurisdiction for Reviewing the Company’s Novel Immune-Modulating Biologic for Treating Coccidiosis in Broiler Chickens
In August 2022, Zivo Bioscience, Inc. (the "Company") announced receipt of a letter from the U.S. Department of Agriculture's (USDA) Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction for reviewing the Company's novel immune-modulating biologic for treating coccidiosis in broiler chickens.